Clinical trials: Inflammatory Disease
Ulcerative Colitis
Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative Colitis
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).
- Trial name
- RISE UP (NCT07136116)
- Where
- 29 sites in Japan
- Volunteers
- 200 people
- Sponsor
- AbbVie
Crohn's Disease
Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease
Human mesenchymal stem cells (MSCs), derived from healthy adult volunteer human donors, can be obtained from bone marrow donation and cultured in the laboratory.
- Trial name
- NCT00294112
- Testing
- Prochymal™ adult human mesenchymal stem cells, adult human mesenchymal stem cells
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Mesoblast, Inc.
Ankylosing Spondylitis
16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis
This study will assess the efficacy and safety of secukinumab in patients with active ankylosing spondylitis who are intolerant to or have had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor therapy.
- Trial name
- MEASURE 1 (NCT01358175)
- Testing
- Secukinumab (75 mg), Secukinumab (150 mg)
- Where
- 67 sites in United States, Belgium and 12 more
- Volunteers
- 371 people
- Sponsor
- Novartis Pharmaceuticals
Overweight or Obesity, Healthy
Berries, Inflammation, and Gut Microbiome
The primary objectives are to characterize changes in indices of systemic and gut inflammation, assess host- and microbial-derived metabolite pools, and describe and link functional metagenomics and metatranscriptomic alterations…
- Trial name
- NCT04100200
- Testing
- Mixed berries, FOS, Control
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Inflammatory Bowel Diseases, Skin Extra-intestinal Manifestations
Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations
The purpose of this phase 2a, proof of concept, open-label clinical study is to evaluate the efficacy and safety of etrasimod (APD334) in inflammatory bowel disease patients with active skin extra-intestinal manifestations.
- Trial name
- NCT03139032
- Testing
- APD334
- Where
- 3 sites in Belgium, Germany and 1 more
- Volunteers
- 1 people
- Sponsor
- Arena Pharmaceuticals
Ulcerative Colitis (UC), Crohn Disease (CD)
The Safety and Efficacy of Good Feeling Power® for IBD Patients
This open-label pilot study aims to evaluate the safety and efficacy of the dietary supplement Good Feeling Power® for patients with mild-to-moderate ulcerative colitis and colonic/ileal Crohn's disease.
- Trial name
- NCT07766733
- Testing
- Good Feeling Power®
- Where
- Spain
- Volunteers
- 36 people
- Sponsor
- Good Feeling Products GmbH
Crohn's Disease
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.
- Trial name
- DUET-CD (NCT05242471)
- Testing
- Guselkumab, Golimumab, JNJ-78934804
- Where
- 456 sites in United States, Australia and 34 more
- Volunteers
- 703 people
- Sponsor
- Janssen Research & Development, LLC
Osteoarthritis
Study of Association of Anti-inflammatory and Anti-rheumatic
Phase III Study, double-blind, comparing association of anti-inflammatory and anti-rheumatic in 375 subjects with knee osteoarthritis.
- Trial name
- ZDPC00213 (NCT02448199)
- Testing
- Meloxicam and Glucosamine, Meloxicam, Glucosamine
- Volunteers
- 375 people
- Sponsor
- Zodiac Produtos Farmaceuticos S.A.
Crohn's Disease
An Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Crohn's Disease
The purpose of this study is to evaluate the efficacy and safety of Inflabloc Cap (Dehydroepiandrosterone [DHEA]) in the treatment of patients with moderately active Crohn's disease.
- Trial name
- NCT00106314
- Testing
- Dehydroepiandrosterone [DHEA]
- Where
- 38 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- Inflabloc Pharmaceuticals
Inflammatory Arthritis, Primary Total Knee Arthroplasty Due to Degenerative Joint Disease (Primary Diagnosis of Osteoarthritis)
A Multi-Center Study Assessing the Safety and Efficacy of the LEGION Medial Stabilized (MS) Insert in Patients Undergoing a Total Knee Arthroplasty (TKA)
The purpose of this study is to assess the long-term safety and performance of the LEGION Medial Stabilized insert and to generate clinical evidence to support and maintain product registration in global markets.
- Conditions
- Inflammatory Arthritis, Primary Total Knee Arthroplasty Due to Degenerative Joint Disease (Primary Diagnosis of Osteoarthritis), Post-traumatic Arthritis
- Trial name
- NCT07199738
- Testing
- Cemented CoCr, Cemented Oxinium, Cementless
- Where
- 4 sites in United States
- Volunteers
- 144 people
- Sponsor
- Smith & Nephew, Inc.
Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia
Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS)
Bronchopulmonary Dysplasia (BPD) is a multi-factorial disease process that is the end result of an immature, surfactant deficient lung that has been exposed to hyperoxia, mechanical ventilation and infection.
- Trial name
- NCT01473264
- Testing
- recombinant human CC10 (rhCC10)
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Clarassance, Inc.
Colitis, Ulcerative
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the efficacy of guselkumab in pediatric participants with moderately to severely active ulcerative colitis at the end of maintenance therapy among participants who were induction…
- Trial name
- QUASAR Jr (NCT06260163)
- Testing
- Guselkumab Subcutaneous, Guselkumab Intravenous
- Where
- 61 sites in United States, Australia and 11 more
- Volunteers
- 112 people
- Sponsor
- Janssen Research & Development, LLC
Relapsing-remitting Multiple Sclerosis
Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
The purpose of this study was to determine the dose-response curve for the MRI-based efficacy of BAF312 compared with placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS), and to characterize its safety and…
- Trial name
- NCT00879658
- Testing
- BAF312
- Where
- 72 sites in United States, Canada and 10 more
- Volunteers
- 297 people
- Sponsor
- Novartis Pharmaceuticals
Ulcerative Colitis
A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting
This study evaluated the quality of life (QOL) and economic impact of adalimumab treatment in participants with ulcerative colitis (UC).
- Trial name
- InspirAda (NCT01550965)
- Testing
- Adalimumab
- Volunteers
- 463 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Colitis, Ulcerative
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis
The purpose of the study is to evaluate the efficacy and safety of LYC-30937-EC given orally once daily in subjects with active ulcerative colitis (UC) defined as a total Mayo score (TMS) of 4-11 inclusive, with an endoscopic…
- Trial name
- NCT02762500
- Testing
- LYC-30937-EC
- Where
- 71 sites in United States, Canada and 5 more
- Volunteers
- 124 people
- Sponsor
- Lycera Corp.
Crohn's Disease
Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease
To compare the efficacy, safety and pharmacokinetics of ABT-874 to placebo in subjects who have moderately to severely active Crohn's Disease.
- Trial name
- NCT00562887
- Testing
- ABT-874
- Where
- 61 sites in United States, Australia and 5 more
- Volunteers
- 246 people
- Sponsor
- Abbott
Macula Edema, Radiation Retinopathy
Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
This phase I trial will assess primarily the safety and secondarily the anti-inflammatory and anti-neovascular effect of Episcleral Celecoxib in patients suffering from macular edema and other inflammatory disorders of the…
- Conditions
- Macula Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane
- Trial name
- NCT04120636
- Testing
- Episcleral Celecoxib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Targeted Therapy Technologies, LLC
Crohn's Disease
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
This is a randomized, double-blind, placebo-controlled, multicenter, and proof of concept study with a parallel group design to evaluate the safety and efficacy of oral Trichuris Suis Ova (TSO) suspension, as compared to placebo…
- Trial name
- TRUST-I (NCT01576471)
- Testing
- Trichuris suis ova (TSO)
- Where
- 73 sites in United States
- Volunteers
- 250 people
- Sponsor
- Coronado Biosciences, Inc.
Crohn Disease
A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the clinical and endoscopic efficacy and safety of ustekinumab in Chinese participants with moderately to severely active Crohn's disease.
- Trial name
- NCT05029921
- Testing
- Ustekinumab
- Where
- 29 sites in China
- Volunteers
- 182 people
- Sponsor
- Janssen Research & Development, LLC
Ulcerative Colitis
Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of GLPG0974 in Subjects With Ulcerative Colitis
Approximately 45 patients suffering from mild to moderate ulcerative colitis will be examined for any side effects (safety and tolerability) that may occur when taking GLPG0974 or matching placebo (2:1 ratio) for 28 days.
- Trial name
- NCT01829321
- Testing
- GLPG0974
- Where
- 16 sites in Belgium, Czechia and 2 more
- Volunteers
- 45 people
- Sponsor
- Lakefront Biotherapeutics NV
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.